Ann Mtg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ann mtg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ann Mtg Today - Breaking & Trending Today

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi). The results showed a significant reduction of albuminuria, a marker of kidney damage,2 by up to 39.5% when BI 690517 was given on top of empagliflozin, a sodium glucose . ....

Rheinland Pfalz , United States , Carinne Brouillon , Katherine Tuttle , J Nephrol Renovasc , Coll Cardiol , Kidney Research Institute , Oxford Population Health , American Society Of Nephrology , Boehringer Ingelheim , Animal Health , Nephrology Division , University Of Washington , American Society , Kidney Week , Principal Study Investigator , Human Pharma , Corporate Headquarters , Ann Mtg , Diabetes Endocrinol ,

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor,. ....

United States , Prnewswire Boehringer Ingelheim , Coll Cardiol , J Nephrol Renovasc , Katherine Tuttle , Carinne Brouillon , Boehringer Ingelheim Pharmaceuticals Inc , Kidney Research Institute , Nephrology Division , Animal Health , American Society Of Nephrology , Boehringer Ingelheim , Oxford Population Health , University Of Washington , Oxford Population , American Society , Kidney Week , Principal Study Investigator , Human Pharma , Corporate Headquarters , Ann Mtg , Diabetes Endocrinol , Ingelheim Pharmaceuticals ,

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Katherine Tuttle , Coll Cardiol , Carinne Brouillon , J Nephrol Renovasc , Nlet Al , Prnewswire Boehringer Ingelheim , Animal Health , Kidney Research Institute , University Of Washington , Oxford Population Health , Nephrology Division , Boehringer Ingelheim , Boehringer Ingelheim Pharmaceuticals Inc , American Society Of Nephrology , Oxford Population , American Society , Kidney Week , Principal Study Investigator , Human Pharma , Corporate Headquarters , Ann Mtg , Diabetes Endocrinol , Ingelheim Pharmaceuticals ,